News

New international partnership promises great potential for next-­generation biopharmaceuticals

Valneva to Present on Lyme and Zika at the 18thWorld Vaccine Congress in Washington, D.C.

The “eternal youth” of cancer cells

Mitral regurgitation influences the course of chronic heart failure

Alzheimer´s disease: patients exhibit changes in certain bloos lipids that are typical of premature ageing

Austrian Society For Stem Cell Research Founded At IMBA

Valneva Reports Positive Phase I Interim Results for Its Lyme Vaccine Candidate VLA15

Seed-Financing round for contextflow

Arsanis Granted Key Patents for ASN100 Covering Cross-Neutralizing S. aureus Toxin Antibodies

Valneva Initiates Phase I Clinical Study to Evaluate Its Single-Shot Vaccine Candidate against Chikungunya

Arsanis Reports Financial Results and Highlights for Fourth Quarter and Full Year 2017

CEPI Partners with Themis Bioscience to Advance Vaccines Against Lassa Fever and MERS

AFFiRiS Announces Results of a Phase I Clinical Study Using AFFITOPEs® PD01A and PD03A, Confirming Safety and Tolerability for Both Compounds as well as Immunogenicity for PD01A in Early MSA patients

Themis Establishes Scientific Advisory Board of Experts in Virology and Vaccine Development

Vitamin A in cattle fodder is potentially protecting against cow´s milk allergy

MR imaging clarifies ambiguous mammography results

Boehringer Ingelheim Office Hours in Vienna on April 19, 2018

TAmiRNA & Vivomicx announce the introduction of new technology to make preclinical drug discovery and drug development more efficient.

Tailor-made cancer treatment: new drugs, new treatment strategies

Optimising healthcare provision in Europe: MedUni Vienna to coordinate EU research programme PECUNIA